Resources
4 Results (showing 1 - 4)
Results sorted by updated date (newest first)
Results sorted by updated date (newest first)
Posted 11/17/2023 (updated 3/28/2024)
The Substance Abuse and Mental Health Services Administration (SAMHSA) has published the new resource "Counseling Approaches To Promote Recovery From Problematic Substance Use and Related Issues". This Treatment Improvement Protocol (TIP) provides guidance to counselors, administrators, and supervisors about recovery-oriented services, supports, and care, allowing them to better serve individuals in or seeking recovery from problematic substance use.
Posted 11/9/2023 (updated 3/28/2024)
The Recovery-Ready Workplace Toolkit: Guidance and Resources for Private and Public Sector Employers was created through the efforts of the Office of National Drug Control Policy, the Domestic Policy Council, and 12 federal departments and independent agencies. It is designed to help businesses and other employers prevent and respond more effectively to substance misuse among employees, build their workforces through hiring of people in recovery, and develop a recovery-supportive culture.
Posted 3/14/2023 (updated 3/27/2024)
Xylazine is a non-opioid that is approved for animals, and not FDA-approved for humans. New York State's Department of Health provides information on what it is, sources and trends, effects, why people use it, why clinicians should be concerned, and other information on Xylazine. Information about Xylazine is important to understand now that it has been showing up in illicit drug supply.
Posted 8/18/2023 (updated 3/26/2024)
The National Institute on Drug Abuse (NIDA) Center for the Clinical Trials Network (CCTN) held an event where health care professionals and federal partners discussed xylazine-related testing, treatment, and wound care. As the White House has deemed fentanyl adulterated with xylazine an emerging threat, it is important to identify and adapt to the rapidly changing practices of patient care.